BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reinecke H, Jürgensmeyer S, Engelbertz C, Gerss J, Kirchhof P, Breithardt G, Bauersachs R, Wanner C. Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study. BMJ Open 2018;8:e022690. [PMID: 30206088 DOI: 10.1136/bmjopen-2018-022690] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Wald R, Dorian P, Harel Z. Benefits and Risks of Anticoagulation in Dialysis Patients With Nonvalvular Atrial Fibrillation: Navigating Through Darkness. J Am Coll Cardiol 2020;75:286-8. [PMID: 31976866 DOI: 10.1016/j.jacc.2019.11.033] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 van Zyl M, Abdullah HM, Noseworthy PA, Siontis KC. Stroke Prophylaxis in Patients with Atrial Fibrillation and End-Stage Renal Disease. J Clin Med 2020;9:E123. [PMID: 31906546 DOI: 10.3390/jcm9010123] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
3 See L, Lee H, Chao T, Li P, Liu J, Wu L, Chang S, Yeh Y, Kuo C, Chan Y, Lip GYH. Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis. Cardiovasc Drugs Ther 2021;35:975-86. [DOI: 10.1007/s10557-020-07108-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Katsanos AH, Kamel H, Healey JS, Hart RG. Stroke Prevention in Atrial Fibrillation: Looking Forward. Circulation 2020;142:2371-88. [DOI: 10.1161/circulationaha.120.049768] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
5 Jegatheswaran J, Hundemer GL, Massicotte-Azarniouch D, Sood MM. Anticoagulation in Patients With Advanced Chronic Kidney Disease: Walking the Fine Line Between Benefit and Harm. Can J Cardiol 2019;35:1241-55. [PMID: 31472820 DOI: 10.1016/j.cjca.2019.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kotalczyk A, Mazurek M, Kalarus Z, Potpara TS, Lip GYH. Stroke prevention strategies in high-risk patients with atrial fibrillation. Nat Rev Cardiol 2021;18:276-90. [PMID: 33110242 DOI: 10.1038/s41569-020-00459-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
7 Magnocavallo M, Bellasi A, Mariani MV, Fusaro M, Ravera M, Paoletti E, Di Iorio B, Barbera V, Della Rocca DG, Palumbo R, Severino P, Lavalle C, Di Lullo L. Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy. J Clin Med 2020;10:E83. [PMID: 33379379 DOI: 10.3390/jcm10010083] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Ha JT, Badve SV, Jun M. Recent evidence for direct oral anticoagulants in chronic kidney disease. Curr Opin Nephrol Hypertens 2019;28:251-61. [PMID: 30789840 DOI: 10.1097/MNH.0000000000000493] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Fawzy AM, Lip GYH. Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation. Expert Opin Drug Metab Toxicol 2019;15:381-98. [PMID: 30951640 DOI: 10.1080/17425255.2019.1604686] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
10 Warkentin L, Hueber S, Deiters B, Klohn F, Kühlein T. Vitamin-K-antagonist phenprocoumon versus low-dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: a real-world analysis of German claims data. Thromb J 2022;20:31. [PMID: 35619140 DOI: 10.1186/s12959-022-00389-9] [Reference Citation Analysis]
11 Ferrari F, da Silveira AD, Martins VM, Franzoni LT, Zimerman LI, Stein R. Direct-Acting Oral Anticoagulants in Atrial Fibrillation: What's New in the Literature. Cardiol Rev 2021;29:120-30. [PMID: 32332235 DOI: 10.1097/CRD.0000000000000312] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Fawzy AM, Yang WY, Lip GY. Safety of direct oral anticoagulants in real-world clinical practice: translating the trials to everyday clinical management. Expert Opin Drug Saf 2019;18:187-209. [PMID: 30712419 DOI: 10.1080/14740338.2019.1578344] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
13 Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Vanassche T, Potpara T, Camm AJ, Heidbüchel H, Lip GYH, Deneke T, Dagres N, Boriani G, Chao TF, Choi EK, Hills MT, Santos IS, Lane DA, Atar D, Joung B, Cole OM, Field M; External reviewers:. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace 2021:euab065. [PMID: 33895845 DOI: 10.1093/europace/euab065] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
14 Kelly DM, Rothwell PM. Prevention and treatment of stroke in patients with chronic kidney disease: an overview of evidence and current guidelines. Kidney Int 2020;97:266-78. [PMID: 31866114 DOI: 10.1016/j.kint.2019.09.024] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
15 Gilyarevskiy SR. Off-Label Medicines Use: Complex Problem of Modern Clinical Practice. Racionalʹnaâ farmakoterapiâ v kardiologii 2020;16:324-34. [DOI: 10.20996/1819-6446-2020-04-14] [Reference Citation Analysis]
16 De Vriese AS, Caluwé R, Van Der Meersch H, De Boeck K, De Bacquer D. Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial. J Am Soc Nephrol 2021;32:1474-83. [PMID: 33753537 DOI: 10.1681/ASN.2020111566] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
17 Kozieł M, Potpara TS, Lip GYH. Triple therapy in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention/stenting. Res Pract Thromb Haemost 2020;4:357-65. [PMID: 32211570 DOI: 10.1002/rth2.12319] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Davis E, Darais D, Fuji K, Nekola P, Bashir K. Prescribing and Safety of Direct-Acting Oral Anticoagulants Compared to Warfarin in Patients with Atrial Fibrillation on Chronic Hemodialysis. Pharmacy (Basel) 2020;8:E37. [PMID: 32164234 DOI: 10.3390/pharmacy8010037] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Abdullah HM, Ullah W, Jafar MS, van Zyl M, Saeed R, Alam M, Alraies MC, Fischman DL. Safety and Efficacy of Apixaban, Rivaroxaban, and Warfarin in End-Stage Renal Disease With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Cardiovasc Revasc Med 2021;30:26-32. [PMID: 34420589 DOI: 10.1016/j.carrev.2020.09.041] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]